Top

BMC Cancer

Published in:

Open Access 01-12-2019 | Endometrial Cancer | Research article

Knockdown of estrogen receptor β increases proliferation and affects the transcriptome of endometrial adenocarcinoma cells

Authors: Oliver Treeck, Elisabeth Diepolder, Maciej Skrzypczak, Susanne Schüler-Toprak, Olaf Ortmann

Published in: BMC Cancer | Issue 1/2019

Abstract

Background

Estrogen receptor β (ERβ) has been repeatedly suggested to play important roles in hormone-dependent cancer like in tumors of the breast, ovary or prostate. In this study, we intended to further elucidate its role in endometrial cancer.

Methods

For this purpose, we knocked down ERβ expression in two endometrial cancer cell lines, the ERα-negative/ERβ-positive line HEC-1A and the ERα/β-positive cell line RL95/2, by means of siRNA transfection. Cell proliferation after transfection was assessed using the fluorescent CTB Assay (Promega). In order to elucidate possible molecular mechanisms which might underlie the effect on proliferation, we performed transcriptome analyses by means of human Affymetrix Human Gene Chip 2.0. Additionally, we treated the employed cell lines with different ERβ modulators to examine their effect on proliferation.

Results

siRNA-mediated knockdown of ERβ significantly increased proliferation of both endometrial cancer cell lines. In HEC-1A cells, proliferation was significantly increased 4, 5 and 6 days after transfection, with a maximum of about 1.7-fold (p < 0.05) on day 6. Endometrial RL95/2 cells with an ERβ knockdown exhibited a clearly enhanced proliferation on day 3 and days 4 to 8, when even 2.4-fold higher numbers of viable cells were detected (p < 0.01). Transcriptome analysis revealed that this was accompanied by increased expression of several genes being known to be upregulated in cancer, including proliferation-associated genes and oncogenes, and by repression of genes associated with differentiation, apoptosis or growth inhibition. Corroborating the observed knockdown effects, treatment with the ERβ antagonists PHTTP and (R, R) THC was also able to induce proliferation of both cell lines.

Conclusions

Our data clearly support the putative role of ERβ as tumor suppressor in endometrium as previously suggested in studies on other tissues and encourage further studies to find out to what extent this molecule might be a potential therapy target in this cancer entity.

Available only for authorised users

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71–96. https://doi.org/10.3322/CA.2007.0010.CrossRefPubMed

Rose PG. Endometrial carcinoma. N Engl J Med. 1996;335:640–9. https://doi.org/10.1056/NEJM199608293350907.CrossRefPubMed

Ulrich LSG. Endometrial cancer, types, prognosis, female hormones and antihormones. Climacteric. 2011;14:418–25. https://doi.org/10.3109/13697137.2010.550974.CrossRefPubMed

Oehler MK, Brand A, Wain GV. Molecular genetics and endometrial cancer. J Br Menopause Soc. 2003;9:27–31.PubMed

Pertschuk LP, Masood S, Simone J, Feldman JG, Fruchter RG, Axiotis CA, Greene GL. Estrogen receptor immunocytochemistry in endometrial carcinoma: a prognostic marker for survival. Gynecol Oncol. 1996;63:28–33. https://doi.org/10.1006/gyno.1996.0273.CrossRefPubMed

Tomica D, Ramić S, Danolić D, Šušnjar L, Perić-Balja M, Puljiz M. Impact of oestrogen and progesterone receptor expression in the cancer cells and myometrium on survival of patients with endometrial cancer. J Obstet Gynaecol. 2018;38:96–102. https://doi.org/10.1080/01443615.2017.1328591.CrossRefPubMed

Smuc T, Rizner TL. Aberrant pre-receptor regulation of estrogen and progesterone action in endometrial cancer. Mol Cell Endocrinol. 2009;301:74–82. https://doi.org/10.1016/j.mce.2008.09.019.CrossRefPubMed

Chakravarty D, Srinivasan R, Ghosh S, Rajwanshi A, Gopalan S. Estrogen receptor beta (ERbeta) in endometrial simple hyperplasia and endometrioid carcinoma. Appl Immunohistochem Mol Morphol. 2008;16:535–42. https://doi.org/10.1097/PAI.0b013e31816755a9.CrossRefPubMed

Jazaeri AA, Nunes KJ, Dalton MS, Xu M, Shupnik MA, Rice LW. Well-differentiated endometrial adenocarcinomas and poorly differentiated mixed mullerian tumors have altered ER and PR isoform expression. Oncogene. 2001;20:6965–9. https://doi.org/10.1038/sj.onc.1204809.CrossRefPubMed

10.

Knapp P, Chabowski A, Błachnio-Zabielska A, Walentowicz-Sadłecka M, Grabiec M, Knapp PA. Expression of estrogen receptors (α, β), cyclooxygenase−2 and aromatase in normal endometrium and endometrioid cancer of uterus. Adv Med Sci. 2013;58:96–103. https://doi.org/10.2478/v10039-012-0055-1.CrossRefPubMed

11.

Häring J, Skrzypczak M, Stegerer A, Lattrich C, Weber F, Görse R, et al. Estrogen receptor β transcript variants associate with oncogene expression in endometrial cancer. Int J Mol Med. 2012;29:1127–36. https://doi.org/10.3892/ijmm.2012.929.CrossRefPubMed

12.

Obata T, Nakamura M, Mizumoto Y, Iizuka T, Ono M, Terakawa J, et al. Dual expression of immunoreactive estrogen receptor β and p53 is a potential predictor of regional lymph node metastasis and postoperative recurrence in endometrial endometrioid carcinoma. PLoS One. 2017;12:e0188641. https://doi.org/10.1371/journal.pone.0188641.CrossRefPubMedPubMedCentral

13.

Treeck O, Juhasz-Boess I, Lattrich C, Horn F, Goerse R, Ortmann O. Effects of exon-deleted estrogen receptor beta transcript variants on growth, apoptosis and gene expression of human breast cancer cell lines. Breast Cancer Res Treat. 2008;110:507–20. https://doi.org/10.1007/s10549-007-9749-7.CrossRefPubMed

14.

Treeck O, Lattrich C, Springwald A, Ortmann O. Estrogen receptor beta exerts growth-inhibitory effects on human mammary epithelial cells. Breast Cancer Res Treat. 2010;120:557–65. https://doi.org/10.1007/s10549-009-0413-2.CrossRefPubMed

15.

Schüler-Toprak S, Häring J, Inwald EC, Moehle C, Ortmann O, Treeck O. Agonists and knockdown of estrogen receptor β differentially affect invasion of triple-negative breast cancer cells in vitro. BMC Cancer. 2016;16:951. https://doi.org/10.1186/s12885-016-2973-y.CrossRefPubMedPubMedCentral

16.

Bossard C, Busson M, Vindrieux D, Gaudin F, Machelon V, Brigitte M, et al. Potential role of estrogen receptor beta as a tumor suppressor of epithelial ovarian cancer. PLoS One. 2012;7:e44787. https://doi.org/10.1371/journal.pone.0044787.CrossRefPubMedPubMedCentral

17.

Lan Y-L, Zou S, Wang X, Lou J-C, Xing J-S, Yu M, Zhang B. Update on the therapeutic significance of estrogen receptor beta in malignant gliomas. Oncotarget. 2017;8:81686–96. https://doi.org/10.18632/oncotarget.20970.CrossRefPubMedPubMedCentral

18.

Sharma V, Verma V, Lal N, Yadav SK, Sarkar S, Mandalapu D, et al. Disulfiram and its novel derivative sensitize prostate cancer cells to the growth regulatory mechanisms of the cell by re-expressing the epigenetically repressed tumor suppressor-estrogen receptor β. Mol Carcinog. 2016;55:1843–57. https://doi.org/10.1002/mc.22433.CrossRefPubMed

19.

Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 2001;25:402–8. https://doi.org/10.1006/meth.2001.1262.CrossRefPubMed

20.

Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 2008;3:1101–8.CrossRefPubMed

21.

Schüler-Toprak S, Moehle C, Skrzypczak M, Ortmann O, Treeck O. Effect of estrogen receptor β agonists on proliferation and gene expression of ovarian cancer cells. BMC Cancer. 2017;17:319. https://doi.org/10.1186/s12885-017-3246-0.CrossRefPubMedPubMedCentral

22.

Mi H, Muruganujan A, Huang X, Ebert D, Mills C, Guo X, Thomas PD. Protocol update for large-scale genome and gene function analysis with the PANTHER classification system (v.14.0). Nat Protoc. 2019;14:703–21. https://doi.org/10.1038/s41596-019-0128-8.CrossRefPubMedPubMedCentral

23.

Compton DR, Sheng S, Carlson KE, Rebacz NA, Lee IY, Katzenellenbogen BS, Katzenellenbogen JA. Pyrazolo1,5-apyrimidines: estrogen receptor ligands possessing estrogen receptor beta antagonist activity. J Med Chem. 2004;47:5872–93. https://doi.org/10.1021/jm049631k.CrossRefPubMed

24.

Chan KK-L, Leung TH-Y, Chan DW, Wei N, Lau GT-Y, Liu SS, et al. Targeting estrogen receptor subtypes (ERα and ERβ) with selective ER modulators in ovarian cancer. J Endocrinol. 2014;221:325–36. https://doi.org/10.1530/JOE-13-0500.CrossRefPubMed

25.

Kraichely DM, Sun J, Katzenellenbogen JA, Katzenellenbogen BS. Conformational changes and coactivator recruitment by novel ligands for estrogen receptor-alpha and estrogen receptor-beta: correlations with biological character and distinct differences among SRC coactivator family members. Endocrinology. 2000;141:3534–45. https://doi.org/10.1210/endo.141.10.7698.CrossRefPubMed

26.

Stettner M, Kaulfuss S, Burfeind P, Schweyer S, Strauss A, Ringert R-H, Thelen P. The relevance of estrogen receptor-beta expression to the antiproliferative effects observed with histone deacetylase inhibitors and phytoestrogens in prostate cancer treatment. Mol Cancer Ther. 2007;6:2626–33. https://doi.org/10.1158/1535-7163.MCT-07-0197.CrossRefPubMed

27.

Cheng J, Lee EJ, Madison LD, Lazennec G. Expression of estrogen receptor beta in prostate carcinoma cells inhibits invasion and proliferation and triggers apoptosis. FEBS Lett. 2004;566:169–72. https://doi.org/10.1016/j.febslet.2004.04.025.CrossRefPubMed

28.

Paruthiyil S, Cvoro A, Tagliaferri M, Cohen I, Shtivelman E, Leitman DC. Estrogen receptor β causes a G2 cell cycle arrest by inhibiting CDK1 activity through the regulation of cyclin B1, GADD45A, and BTG2. Breast Cancer Res Treat. 2011;129:777–84. https://doi.org/10.1007/s10549-010-1273-5.CrossRefPubMed

29.

Treeck O, Pfeiler G, Mitter D, Lattrich C, Piendl G, Ortmann O. Estrogen receptor {beta}1 exerts antitumoral effects on SK-OV-3 ovarian cancer cells. J Endocrinol. 2007;193:421–33. https://doi.org/10.1677/JOE-07-0087.CrossRefPubMed

30.

Treeck O, Pfeiler G, Horn F, Federhofer B, Houlihan H, Vollmer A, Ortmann O. Novel estrogen receptor beta transcript variants identified in human breast cancer cells affect cell growth and apoptosis of COS-1 cells. Mol Cell Endocrinol. 2007;264:50–60. https://doi.org/10.1016/j.mce.2006.10.003.CrossRefPubMed

31.

Halon A, Nowak-Markwitz E, Maciejczyk A, Pudelko M, Gansukh T, Györffy B, et al. Loss of estrogen receptor beta expression correlates with shorter overall survival and lack of clinical response to chemotherapy in ovarian cancer patients. Anticancer Res. 2011;31:711–8.PubMed

32.

Rody A, Holtrich U, Solbach C, Kourtis K, von Minckwitz G, Engels K, et al. Methylation of estrogen receptor beta promoter correlates with loss of ER-beta expression in mammary carcinoma and is an early indication marker in premalignant lesions. Endocr Relat Cancer. 2005;12:903–16. https://doi.org/10.1677/erc.1.01088.CrossRefPubMed

33.

Levakov AF, Kaćanski MM, Vucković N, Zivojinov M, Amidzić J, Sabo JI. The expression and localization of estrogen receptor beta in hyperplastic and neoplastic prostate lesions. Vojnosanit Pregl. 2015;72:906–13.CrossRefPubMed

34.

Omoto Y, Iwase H. Clinical significance of estrogen receptor β in breast and prostate cancer from biological aspects. Cancer Sci. 2015;106:337–43. https://doi.org/10.1111/cas.12613.CrossRefPubMedPubMedCentral

35.

Witek A, Skałba P, Paul M, Graniczka M, Mazurek U, Chromy G, Wilczok T. Ocena profilu ekspresji receptora estrogenowego beta i jego izoform ER-beta/delta 5/6 i ER-beta/delta 6 w gruczolakoraku endometrium. Ginekol Pol. 2003;74:897–902.PubMed

36.

Pinton G, Thomas W, Bellini P, Manente AG, Favoni RE, Harvey BJ, et al. Estrogen receptor β exerts tumor repressive functions in human malignant pleural mesothelioma via EGFR inactivation and affects response to gefitinib. PLoS One. 2010;5:e14110. https://doi.org/10.1371/journal.pone.0014110.CrossRefPubMedPubMedCentral

37.

Lazennec G. Estrogen receptor beta, a possible tumor suppressor involved in ovarian carcinogenesis. Cancer Lett. 2006;231:151–7. https://doi.org/10.1016/j.canlet.2005.01.021.CrossRefPubMedPubMedCentral

38.

Tremblay A, Giguère V. Contribution of steroid receptor coactivator-1 and CREB binding protein in ligand-independent activity of estrogen receptor beta. J Steroid Biochem Mol Biol. 2001;77:19–27.CrossRefPubMed

39.

Coopes A, Henry CE, Llamosas E, Ford CE. An update of Wnt signalling in endometrial cancer and its potential as a therapeutic target. Endocr Relat Cancer. 2018. https://doi.org/10.1530/ERC-18-0112.CrossRef

40.

Redon R, Hussenet T, Bour G, Caulee K, Jost B, Muller D, et al. Amplicon mapping and transcriptional analysis pinpoint cyclin L as a candidate oncogene in head and neck cancer. Cancer Res. 2002;62:6211–7.PubMed

41.

Muller D, Millon R, Théobald S, Hussenet T, Wasylyk B, Du Manoir S, Abecassis J. Cyclin L1 (CCNL1) gene alterations in human head and neck squamous cell carcinoma. Br J Cancer. 2006;94:1041–4. https://doi.org/10.1038/sj.bjc.6603036.CrossRefPubMedPubMedCentral

42.

D'Arcy P, Maruwge W, Wolahan B, Ma L, Brodin B. Oncogenic functions of the cancer-testis antigen SSX on the proliferation, survival, and signaling pathways of cancer cells. PLoS One. 2014;9:e95136. https://doi.org/10.1371/journal.pone.0095136.CrossRefPubMedPubMedCentral

43.

Banito A, Li X, Laporte AN, Roe J-S, Sanchez-Vega F, Huang C-H, et al. The SS18-SSX Oncoprotein hijacks KDM2B-PRC1.1 to drive synovial sarcoma. Cancer Cell. 2018;34:346–8. https://doi.org/10.1016/j.ccell.2018.07.006.CrossRefPubMedPubMedCentral

44.

van Pham TH, Hartomo TB, Lee MJ, Hasegawa D, Ishida T, Kawasaki K, et al. Rab15 alternative splicing is altered in spheres of neuroblastoma cells. Oncol Rep. 2012;27:2045–9. https://doi.org/10.3892/or.2012.1731.CrossRefPubMed

45.

Nishimura N, van Huyen Pham T, Hartomo TB, Lee MJ, Hasegawa D, Takeda H, et al. Rab15 expression correlates with retinoic acid-induced differentiation of neuroblastoma cells. Oncol Rep. 2011;26:145–51. https://doi.org/10.3892/or.2011.1255.CrossRefPubMed

46.

Chen H, Wang S, Zhang H, Nice EC, Huang C. Nicotinamide phosphoribosyltransferase (Nampt) in carcinogenesis: new clinical opportunities. Expert Rev Anticancer Ther. 2016;16:827–38. https://doi.org/10.1080/14737140.2016.1190649.CrossRefPubMed

47.

Sampath D, Zabka TS, Misner DL, O'Brien T, Dragovich PS. Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) as a therapeutic strategy in cancer. Pharmacol Ther. 2015;151:16–31. https://doi.org/10.1016/j.pharmthera.2015.02.004.CrossRefPubMed

48.

Vicente C, Vazquez I, Conchillo A, García-Sánchez MA, Marcotegui N, Fuster O, et al. Overexpression of GATA2 predicts an adverse prognosis for patients with acute myeloid leukemia and it is associated with distinct molecular abnormalities. Leukemia. 2012;26:550–4. https://doi.org/10.1038/leu.2011.235.CrossRefPubMed

49.

Böhm M, Locke WJ, Sutherland RL, Kench JG, Henshall SM. A role for GATA-2 in transition to an aggressive phenotype in prostate cancer through modulation of key androgen-regulated genes. Oncogene. 2009;28:3847–56. https://doi.org/10.1038/onc.2009.243.CrossRefPubMed

50.

Rodriguez-Bravo V, Carceles-Cordon M, Hoshida Y, Cordon-Cardo C, Galsky MD, Domingo-Domenech J. The role of GATA2 in lethal prostate cancer aggressiveness. Nat Rev Urol. 2017;14:38–48. https://doi.org/10.1038/nrurol.2016.225.CrossRefPubMed

51.

Deryusheva IV, Tsyganov M, Garbukov EY, Ibragimova MK, Kzhyshkovska JG, Slonimskaya E, et al. Genome-wide association study of loss of heterozygosity and metastasis-free survival in breast cancer patients. Exp Oncol. 2017;39:145–50.CrossRefPubMed

52.

Frontini M, Soutoglou E, Argentini M, Bole-Feysot C, Jost B, Scheer E, Tora L. TAF9b (formerly TAF9L) is a bona fide TAF that has unique and overlapping roles with TAF9. Mol Cell Biol. 2005;25:4638–49. https://doi.org/10.1128/MCB.25.11.4638-4649.2005.CrossRefPubMedPubMedCentral

53.

Yu F, Bracken CP, Pillman KA, Lawrence DM, Goodall GJ, Callen DF, Neilsen PM. p53 represses the oncogenic Sno-MiR-28 derived from a SnoRNA. PLoS One. 2015;10:e0129190. https://doi.org/10.1371/journal.pone.0129190.CrossRefPubMedPubMedCentral

54.

Boesch M, Sopper S, Marth C, Fiegl H, Wiedemair A, Rössler J, et al. Evaluation of Vav3.1 as prognostic marker in endometrial cancer. J Cancer Res Clin Oncol. 2018;144:2067–76. https://doi.org/10.1007/s00432-018-2725-2.CrossRefPubMedPubMedCentral

55.

Li M, Zhang S, Wu N, Wu L, Wang C, Lin Y. Overexpression of miR-499-5p inhibits non-small cell lung cancer proliferation and metastasis by targeting VAV3. Sci Rep. 2016;6:23100. https://doi.org/10.1038/srep23100.CrossRefPubMedPubMedCentral

56.

Byrne C, Miclet E, Broutin I, Gallo D, Pelekanou V, Kampa M, et al. Identification of polyproline II regions derived from the proline-rich nuclear receptor coactivators PNRC and PNRC2: new insights for ERα coactivator interactions. Chirality. 2013;25:628–42. https://doi.org/10.1002/chir.22188.CrossRefPubMed

57.

Zhou GQ, Baranov V, Zimmermann W, Grunert F, Erhard B, Mincheva-Nilsson L, et al. Highly specific monoclonal antibody demonstrates that pregnancy-specific glycoprotein (PSG) is limited to syncytiotrophoblast in human early and term placenta. Placenta. 1997;18:491–501.CrossRefPubMed

58.

Yi N, Liao Q-P, Li Z-H, Xie B-J, Hu Y-H, Yi W, Liu M. RNA interference-mediated targeting of DKK1 gene expression in Ishikawa endometrial carcinoma cells causes increased tumor cell invasion and migration. Oncol Lett. 2013;6:756–62. https://doi.org/10.3892/ol.2013.1439.CrossRefPubMedPubMedCentral

Title: Knockdown of estrogen receptor β increases proliferation and affects the transcriptome of endometrial adenocarcinoma cells
Authors: Oliver Treeck
Elisabeth Diepolder
Maciej Skrzypczak
Susanne Schüler-Toprak
Olaf Ortmann
Publication date: 01-12-2019
Publisher: BioMed Central
Keywords: Endometrial Cancer
Endometrial Cancer
Estrogens
Published in: BMC Cancer / Issue 1/2019
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-019-5928-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2019

Malignant transformation of vaginal adenosis to clear cell carcinoma without prenatal diethylstilbestrol exposure: a case report and literature review

Cancer-related concerns and needs among young adults and children on cancer treatment in Tanzania: a qualitative study

Potential genetic modifiers for somatic EGFR mutation in lung cancer: a meta-analysis and literature review

Diagnostic and grading accuracy of 18F-FDOPA PET and PET/CT in patients with gliomas: a systematic review and meta-analysis

Clinicopathological characteristics and health care for Tibetan women with breast cancer: a cross-sectional survey

Keynote webinar | Spotlight on antibody–drug conjugates in cancer